Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 103

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 103
---
 that has completed Phase II clinical development studies.
IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12
and interferon gamma, at the tumor site. Additionally, the Company has entered into a first-in-human study of its COVID-19 booster vaccine
(IMNN-101). We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients
with difficult-to-treat conditions.

Technology Platform

Imunon’s technology platform is optimized for
the delivery of DNA and mRNA therapeutics via synthetic non-viral carriers and is capable of providing cell transfection for double-stranded
DNA plasmids and large therapeutic RNA segments such as mRNA. There are two components to the system, a backbone with plasmid DNA or mRNA
payload encoding therapeutic proteins, or pathogen antigens or tumor associated antigens or cancer neoantigens and a delivery system.
The delivery system is designed to protect the DNA or mRNA from degradation and promote trafficking into cells and through intracellular
compartments. We designed the delivery system by chemically modifying the low molecular weight polymer to improve its gene transfer activity
without increasing toxicity. We believe that our non-viral DNA technology may be a viable alternative to current approaches to gene delivery
due to several distinguishing characteristics, including enhanced molecular versatility that allows for complex modifications to potentially
improve activity and safety.

The biocompatibility of these polymers reduces the
risk of adverse immune response, thus allowing for repeated administration. Compared to naked DNA or cationic lipids, we believe that
our delivery systems are generally more efficient, cost effective and have a more favorable safety profile. We believe that these advantages
place Imunon in a position to capitalize on this technology platform.

14

THERAPLAS MODALITY: IMNN-001 DEVELOPMENT
PROGRAM

Ovarian Cancer Overview

Ovarian cancer is the most lethal of gynecological
malignancies among women with more than 60% of women dying within five years of diagnosis. This poor outcome is due in part to the lack
of effective prevention and early detection strategies. There were approximately 20,000 new cases of ovarian cancer in the U.S. in 2021
with an estimated 13,000 deaths. Mortality rates for ovarian cancer declined very little in the last 40 years due to the unavailability
of detection tests and improved treatments.